Li Keqiang's India Visit
With wary eye on the U.S., China courts India
Chinese Premier Li Keqiang, smiling and effusive, was out to smooth ruffled feathers in India this week, promising to ease tensions and increase trade between Asia's fastest growing economies in his first trip overseas since taking office. Full Article | Slideshow
REUTERS SHOWCASE
Buy, Sell or Hold?
Confused while buying stocks? Get buy, sell or hold recommendations from VantageTrade. Full Coverage
Reuters India Mobile
Get the latest news on the go. Visit Reuters India on your mobile device. Full Coverage
Credit Suisse upgrades Dr Reddy's on U.S. outlook
Track Markets: BSE Sectoral Indices
Track and analyse performance of all BSE sectoral indices and other global indices on a single page. Full Coverage
A pharmacist gives free medicine provided by the government, to a patient inside a government hospital in Kolkata July 3, 2012.
Credit: Reuters/Rupak De Chowdhuri/Files
Reuters Market Eye - Credit Suisse upgrades Dr. Reddy's Laboratories(REDY.NS) to 'outperform' from 'neutral' and raises its target price to 2,150 rupees from 1,900 rupees, citing expectations for a strong pick up in U.S. sales in the coming quarters.
Credit Suisse also notes the market share for Dr. Reddy's Metoprolol drug, used for hypertension, is increasing.
Dr. Reddy's also expects upcoming approval of two limited competition products in the United States, Credit Suisse says after meeting with the drug maker's management.
Dr. Reddy's also expects fiscal 2015 growth in the United States to be stronger than fiscal 2014 due to some "significant" launches.
- Tweet this
- Link this
- Share this
- Digg this
- Reprints
Follow Reuters